Alterity Therapeutics Ltd. (AU:ATH) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Alterity Therapeutics has reported promising interim data from its Phase 2 clinical trials of ATH434, showing potential to modify disease progression in Multiple System Atrophy (MSA). With a cash balance of A$9.28 million, the company remains optimistic as it anticipates releasing topline results in 2025. Additionally, Alterity has strengthened its leadership by appointing Abby Macnish Niven as CFO.
For further insights into AU:ATH stock, check out TipRanks’ Stock Analysis page.
